BOTHELL, Wash., Jan. 26 /PRNewswire-FirstCall/ -- Quinton Cardiology Systems, Inc. , a global leader in advanced cardiology products, announced recently that it added a new electrocardiograph (ECG), the Eclipse Premier, to its product line.
(Photo: http://www.newscom.com/cgi-bin/prnh/20040715/SEQUINTONCARDLOGO )
Use of Eclipse Premier can lead to quicker diagnoses, as health practitioners can receive orders and instantly transmit test results via its built-in wireless data sharing capabilities. Workload is also streamlined with an easy-to-use barcode capability, helping to ensure accurate patient identification and documentation.
“The wireless feature has brought the efficiency of our ECG department to a new level,” said Sonya Gregg, director of non-invasive cardiology at Winchester Hospital, Winchester, Virginia, “and a number of steps have been taken out of our ECG process as a result.” “The Eclipse carts have always been very user friendly, but the new Premiers are much faster. We are very happy with these machines,” added Cindy Guerin, lead ECG technician at Winchester Hospital.
The Eclipse Premier also takes advantage of the advanced interpretation algorithm, developed by the Glasgow Royal Infirmary at the University of Glasgow (Scotland), which takes into account all five important criteria for clinical interpretation: age, race, gender, medications and clinical classification. This can be critical, as ECG patterns for patients from different ethnic backgrounds and with differing medical conditions can vary greatly.
“The Eclipse Premier completes our portfolio of ECG products and strengthens our presence in the diagnostic cardiology market. This product, combined with Quinton’s powerful Pyramis ECG data management system, positions us for significant growth in acute care,” said Atul Jhalani, vice president of marketing.
About Quinton Cardiology Systems:
Quinton develops, manufactures, markets, and services a family of advanced cardiology products used in the diagnosis, monitoring and management of patients with cardiovascular disease. Quinton markets its products under the Quinton and Burdick brand names. Quinton shares are quoted on the NASDAQ National Market under the trading symbol “QUIN.” For more information, visit the Quinton web site at http://www.quinton.com/ or contact Quinton at 800-426-0337.
This press release contains statements which are forward-looking statements under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release relate to expected future revenue arising from future sales of the Eclipse Premier product and the Pyramis ECG data management system. Actual results could vary significantly from the results expressed or implied by these forward-looking statements due to many factors, including competition from others in the industry, and other risk factors described in the Annual Report on Form 10-K and other documents filed by Quinton with the Securities and Exchange Commission. Quinton undertakes no obligation to update the information contained herein.
CONTACT: Mike Matysik, Senior vice president and chief financial officer of Quinton Cardiology Systems, +1-425-402-2009.
Photo: http://www.newscom.com/cgi-bin/prnh/20040715/SEQUINTONCARDLOGOAP Archive: http://photoarchive.ap.org/PRN Photo Desk, photodesk@prnewswire.comQuinton Cardiology Systems, Inc.
CONTACT: Mike Matysik, Senior vice president and chief financial officerof Quinton Cardiology Systems, +1-425-402-2009
Web site: http://www.quinton.com/